Skip to main content

Table 1 General characteristics of patients in the two groups

From: α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Parameters Control (n = 19) Miglitol-treated (n = 18) P value
Men (%) 15 (79) 16 (89) 0.659
Age (years) 63 (13) 62 (12) 0.855
Body weight (kg) 69.9 (13.8) 70.9 (15.7) 0.855
Body mass index (kg/m2) 26.2 (4.7) 25.3 (4.3) 0.536
Systolic blood pressure (mmHg) 119 (20) 116 (19) 0.665
Diastolic blood pressure (mmHg) 68 (10) 67 (10) 0.866
Heart rate (beats/min) 75 (14) 76 (10) 0.794
Left ventricular ejection fraction (%) 53 (13) 54 (10) 0.760
Fasting plasma glucose (mmol/L) 7.94 (2.94) 7.83 (1.78) 0.870
HbA1c (%) 6.5 (1.1) 6.8 (0.9) 0.357
HbA1c (mmol/mol) 47.5 (11.5) 50.8 (13.7) 0.357
1,5-anhydro-d-glucitol (µg/mL) 16.0 (10.5) 12.3 (8.1) 0.240
Total cholesterol (mmol/L) 4.55 (0.93) 4.91 (1.19) 0.329
LDL cholesterol (mmol/L) 2.74 (0.75) 2.92 (0.93) 0.534
HDL cholesterol (mmol/L) 1.19 (0.34) 1.32 (0.36) 0.300
Triglyceride (mmol/L) 1.35 (0.61) 1.47 (0.98) 0.673
Non-HDL cholesterol (mmol/L) 3.36 (0.85) 3.59 (1.19) 0.528
Creatinine (µmol/L) 73.4 (17.7) 75.1 (18.6) 0.751
  1. Values are mean (SD) or n (%)
  2. LDL low-density lipoprotein, HDL high-density lipoprotein